Literature DB >> 22094200

Clinimetric evaluations of patients with chronic widespread pain.

Fausto Salaffi1, Piercarlo Sarzi-Puttini, Alessandro Ciapetti, Fabiola Atzeni.   

Abstract

Assessing chronic widespread pain (CWP) and its impact on physical, emotional and social function requires multidimensional qualitative and health-related quality of life (HRQL) instruments. The recommendations of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) concerning outcome measurements for pain trials are useful for making routine assessments, the most significant of which include pain, fatigue, disturbed sleep, physical functioning, emotional functioning, patient global ratings of satisfaction and HRQL. However, despite the growing spread of instruments and theoretical publications devoted to measuring the various aspects of chronic pain, there is little widespread agreement, and no unified approach has yet been devised. There is therefore still considerable scope for the development of consensus around a core set of measures and response criteria, as well as for the development and refinement of the related instruments, standardised assessor training, the cross-cultural adaptation of health status questionnaires, electronic data capture and the introduction of valid, reliable and responsive standardised quantitative measurements into routine clinical care. Clinicians need to be aware of the psychometric properties of the instruments used, including their levels of imprecision and minimum clinically important differences (those indicating a meaningful change in clinical status). This article reviews a selection of the instruments used to assess CWP patients, including validated newly developed and well-established screening instruments, and discusses their advantages and limitations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22094200     DOI: 10.1016/j.berh.2011.01.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  7 in total

1.  Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity.

Authors:  Fausto Salaffi; Rossella De Angelis; Marina Carotti; Marwin Gutierrez; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Rheumatol Int       Date:  2014-02-08       Impact factor: 2.631

2.  The value of ultrasound and magnetic resonance imaging scoring systems in explaining handgrip strength and functional impairment in rheumatoid arthritis patients: a pilot study.

Authors:  Fausto Salaffi; Marina Carotti; Marco Di Carlo; Luca Ceccarelli; Sonia Farah; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2022-05-14       Impact factor: 6.313

3.  The Brazilian version of STarT Back Screening Tool - translation, cross-cultural adaptation and reliability.

Authors:  Bruna Pilz; Rodrigo A Vasconcelos; Freddy B Marcondes; Samuel S Lodovichi; Wilson Mello; Débora B Grossi
Journal:  Braz J Phys Ther       Date:  2014-08-29       Impact factor: 3.377

4.  Rational and design of an individual participant data meta-analysis of spinal manipulative therapy for chronic low back pain-a protocol.

Authors:  A de Zoete; M R de Boer; M W van Tulder; S M Rubinstein; M Underwood; J A Hayden; J Kalter; R Ostelo
Journal:  Syst Rev       Date:  2017-01-26

Review 5.  Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway.

Authors:  Fausto Salaffi; Giovanni Giacobazzi; Marco Di Carlo
Journal:  Pain Res Manag       Date:  2018-02-07       Impact factor: 3.037

6.  The Patient-Reported Outcomes Thermometer-5-Item Scale (5T-PROs): Validation of a New Tool for the Quick Assessment of Overall Health Status in Painful Rheumatic Diseases.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Sonia Farah
Journal:  Pain Res Manag       Date:  2018-10-23       Impact factor: 3.037

7.  Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis.

Authors:  Fabio Cacciapaglia; Maria Grazia Anelli; Daniela Rizzo; Emma Morelli; Daniela Mazzotta; Crescenzio Scioscia; Florenzo Iannone; Giovanni Lapadula
Journal:  J Int Med Res       Date:  2016-09       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.